Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thorsten Naumann is active.

Publication


Featured researches published by Thorsten Naumann.


Journal of Cheminformatics | 2012

Ligand based lead generation - considering chemical accessibility in rescaffolding approaches via BROOD

Li-hsing Wang; Andreas Evers; Peter Monecke; Thorsten Naumann

In pharmaceutical industry ligand based approaches like scaffold hopping, scaffold decoration and me-too approaches, are used to generate lead structures in discovery projects. We use several tools to generate novel lead structures, such as BROOD [1]. BROOD is a software tool which explores chemical space around query molecules based on shape similarity and electrostatics, and it generates analogs of a reference molecule by replacing a selected moiety with fragments from in silico fragment databases. The content of these fragment databases has an essential influence on the molecules generated by BROOD. Due to the amount of resources required to synthesize novel chemical compounds, an easy access to chemical compounds is crucial for the broad applicability and for the acceptance of in silico approaches which propose novel molecules to the synthetic chemist. In order to consider synthetic accessibility of in silico generated molecules, we use our inhouse libraries of drug-like and chemically feasible molecules for the in silico fragment generation. In addition, we implemented fragmentation rules which reflect the (retro-)synthetic access to these molecules. The combination of (retro-)synthesis rules and fragments of existing compounds leads mainly to synthetically accessible compound proposals. To identify relevant available compounds, we implemented an approach where in silico generated molecules are used as search queries to search in inhouse available compound libraries, e.g. via ROCS [2]. This approach leads directly to internally existing compounds which can be ordered for experimental testing. However, if novel chemical matter is desired, chemical synthesis is necessary. Therefore, as a further extension of our approach, we started from available chemical reagents as input for our in silico fragment databases. The available reagents are detected by well-defined chemical reactions, converted to fragments and stored in the in silico fragment databases. As the chemical reactions are considered during the virtual synthesis step, the synthetic accessibility of compound proposals is increased. We present the concept of these approaches, examples and typical applications for different targets.


Journal of Medicinal Chemistry | 2002

Structural Classification of Protein Kinases Using 3D Molecular Interaction Field Analysis of Their Ligand Binding Sites: Target Family Landscapes

Thorsten Naumann; Hans Matter


Combinatorial Chemistry & High Throughput Screening | 2001

Computational Approaches Towards the Rational Design of Drug-like Compound Libraries

Hans Matter; Karl-Heinz Barighaus; Thorsten Naumann; Thomas Klabunde; Bernard Pirard


Archive | 2003

Pyridazinone derivatives as gsk-3beta inhibitors

Swen Hoelder; Thorsten Naumann; Karl Schoenafinger; David William Will; Hans Matter; Guenter Mueller; Suisse Dominique Le; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi


Journal of Medicinal Chemistry | 2005

Multiple-Ligand-Based Virtual Screening: Methods and Applications of the MTree Approach

Gerhard Hessler; Marc Zimmermann; Hans Matter; Andreas Evers; Thorsten Naumann; Thomas Lengauer; Matthias Rarey


Archive | 2003

Pyridazinone derivatives as cdk2-inhibitors

Swen Hoelder; Thorsten Naumann; Karl Schoenafinger; David William Will; Hans Matter; Guenter Mueller; Suisse Dominique Le; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi; Cécile Combeau; Ingrid Sassoon; Anke Steinmetz


Archive | 2003

Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase

Stefanie Flohr; Thorsten Naumann


Archive | 2002

New 4-(carboxamido or acylamino)-6-(hetero)aryl-pyridazinone derivatives are tau-protein phosphorylation inhibitors useful e.g. for treating neurodegenerative diseases, diabetes, hypertension or cancer

Dominique Lesuisse; Franck Halley; Bernard Baudoin; Thomas Rooney; Swen Hoelder; Thorsten Naumann; Gilles Tiraboschi


Archive | 2003

Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them

Swen Hölder; Thorsten Naumann; Karl Schönafinger; David William Will; Hans Matter; Günther Müller; Dominique Le Suisse; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi; Cécile Combeau; Ingrid Sassoon; Anke Steinmetz


Chemoinformatics for Drug Discovery | 2013

EXPLORATION OF STRUCTURE–ACTIVITY RELATIONSHIPS (SARs) AND TRANSFER OF KEY ELEMENTS IN LEAD OPTIMIZATION

Hans Matter; Stefan Güssregen; Friedemann Schmidt; Gerhard Hessler; Thorsten Naumann; Karl-Heinz Baringhaus

Collaboration


Dive into the Thorsten Naumann's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge